Sophiris Bio Inc.
1258 Prospect Street
La Jolla
California
92037
United States
Tel: 858-777-1760
Website: http://www.sophirisbio.com/
Email: info@sophirisbio.com
About Sophiris Bio Inc.
Sophiris Bio is a biopharmaceutical company developing PRX302, a clinical-stage, targeted therapy for the treatment of urological diseases.YEAR FOUNDED:
May 2003
LEADERSHIP:
CEO: Randall Woods
CFO: Peter Slover
CLINICAL TRIAL:
Please click here for clinical trial information.
95 articles about Sophiris Bio Inc.
-
Sophiris Bio To Shut Down Operations
5/18/2020
Sophiris Bio Inc., announced that its board of directors has formally approved an immediate shutdown of the operations of the Company.
-
Sophiris Bio Reports Third Quarter 2019 Financial Results and Recent Corporate Highlights
11/7/2019
Sophiris Bio Inc., a biopharmaceutical company studying topsalysin, a first-in-class, pore-forming protein, in late-stage clinical trials for the treatment of patients with urological diseases, reported financial results for the third quarter 2019 and provided an overview of recent corporate highlights.
-
Sophiris Bio to Present at the H.C. Wainwright 21st Annual Global Investment Conference
8/30/2019
Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"), today announced that Randall E. Woods, president and chief executive officer, will present a corporate overview at the H.C. Wainwright 21st Annual Global Investment Conference on Monday, September 9, 2019 at 3:00 p.m. EDT in New York, NY.
-
Sophiris Bio Announces Completion of $4.0 Million Registered Direct Offering
8/30/2019
Sophiris Bio Inc. (Nasdaq: SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company studying topsalysin (PRX302), a first-in-class, pore-forming protein, in late-stage clinical trials for the treatment of patients with urological diseases, today announced the completion of its previously announced registered direct offering of 5,333,334 common shares
-
Sophiris Bio Announces $4.0 Million Registered Direct Offering
8/27/2019
Sophiris Bio Inc. (Nasdaq: SPHS) (the "Company" or "Sophiris"), today announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor for the issuance and sale of 5,333,334 of its common shares
-
Sophiris Bio Reports Second Quarter 2019 Financial Results and Recent Corporate Highlights
8/9/2019
Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company studying topsalysin (PRX302), a first-in-class, pore-forming protein, in late-stage clinical trials for the treatment of patients with urological diseases, today reported financial results for the second quarter 2019 and recent corporate highlights.
-
Sophiris Bio Receives Positive Feedback from European Medicines Agency Regarding Phase 3 Localized Prostate Cancer Clinical Trial Design
6/19/2019
Conference call scheduled for today at 9:30 a.m. EDT
-
Sophiris Bio Reports First Quarter 2019 Financial Results
5/9/2019
Sophiris Bio Inc. reported financial results for the first quarter of 2019.
-
Sophiris Bio to Present at Two Upcoming Investor Conferences
4/2/2019
Sophiris Bio Inc. announced that Randall E. Woods, president and chief executive officer, will present at two upcoming healthcare-focused investor conferences.
-
Sophiris Bio Reports Fourth Quarter 2018 and Year-end Financial Results and Recent Corporate Highlights
3/13/2019
Sophiris Bio is a first-in-class, pore-forming protein, in late-stage clinical trials for the treatment of patients with urological diseases
-
Although Sophiris Bio plans to continue development, investors weren’t enthused, letting stock plunge more than 38 percent after the company released mixed results from its Phase IIb clinical trial of topsalysin in prostate cancer.
-
Sophiris Bio Provides Updates on Phase 2b Localized Prostate Cancer Trial
12/17/2018
Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company studying topsalysin (PRX302), a first-in-class, pore-forming protein, in late-stage clinical trials for the treatment of patients with urological diseases, today provides an update from its Phase 2b study of topsalysin
-
Sophiris Bio to Present at the 2018 Piper Jaffray Healthcare Conference
11/15/2018
Sophiris Bio Inc. today announced that Randall E. Woods, president and chief executive officer, will present a corporate overview at the Piper Jaffray Healthcare Conference on Tuesday, November 27, 2018 at 2:00 p.m. ET in New York, NY.
-
Sophiris Bio Reports Third Quarter 2018 Financial Results and Recent Corporate Highlights
11/13/2018
Sophiris Bio Inc. today reported financial results for the third quarter 2018 and recent corporate highlights.
-
Sophiris Bio to Present at the Cantor Global Healthcare Conference
9/25/2018
Sophiris Bio Inc. today announced that Randall E. Woods, president and chief executive officer, will present a corporate overview at the Cantor Global Healthcare Conference on Tuesday, October 2, 2018 at 4:35 p.m. EDT in New York, NY.
-
Sophiris Bio to Present at the H.C. Wainwright 20th Annual Global Investment Conference
8/29/2018
Sophiris Bio Inc. today announced that Randall E. Woods, president and chief executive officer, will present a corporate overview at the H.C. Wainwright 20th Annual Global Investment Conference on Wednesday, September 5, 2018 at 10:50 a.m. EDT in New York, NY.
-
Sophiris Bio Reports Second Quarter 2018 Financial Results and Recent Corporate Highlights
8/14/2018
Sophiris Bio Inc. reported financial results for the second quarter 2018 and recent corporate highlights.
-
Sophiris Bio Reports Top-Line Interim Safety and Biopsy Findings For its Phase 2b Clinical Trial of Topsalysin in Localized Prostate Cancer
6/25/2018
A single administration of topsalysin continues to demonstrate an ability to ablate targeted prostate cancer cells with 10 of 35 patients (29%) demonstrating a clinical response of which 6 patients had a complete ablation with no detectable cancer on targeted biopsy of the treated area.
-
Although it’s great to report on successful clinical trial results, the reality is that only about one in 10 drugs make it to approval. With that number in mind, here are a couple companies reporting problematic clinical trials today.
-
Sophiris Bio Reports Fourth Quarter and Full Year 2017 Financial Results and Key Corporate Highlights
3/21/2018
Sophiris Bio Inc. reported fourth quarter and full year 2017 financial results and key corporate highlights.